DaiichiSankyo

AstraZeneca and Daiichi's Innovative Breast Cancer Drug Receives EU Approval

2 months ago

In a significant development for breast cancer treatment, AstraZeneca and Daiichi Sankyo have received endorsement from the European Union for their groundbreaking drug designed to combat one of the most challenging forms of the disease. This approval marks a pivotal moment in the fight against cancer, promising hope to countless patients across Europe.

Astra Daiichi's Drug Approved for Expanded Use in Breast Cancer Patients

2 months ago

In a significant breakthrough for breast cancer treatment, AstraZeneca and Daiichi Sankyo’s drug, Enhertu, has received approval for wider usage amongst patients suffering from HER2-positive breast cancer. This announcement, which has sent ripples through the medical community, comes as a ray of hope for those combating this aggressive form of cancer.

Daiichi Sankyo Soars After Breakthrough Cancer Drug Approval

3 months ago

In a significant development that has captured the attention of investors and the medical community alike, shares of Daiichi Sankyo Co., a prominent Japanese pharmaceutical firm, have experienced a remarkable surge, marking their most substantial single-day gain in over five months. This upswing followed the groundbreaking approval of its innovative cancer treatment, which promises to offer new hope for patients battling specific forms of cancer.

AstraZeneca and Daiichi Sankyo Celebrate FDA Approval for Breakthrough Breast Cancer Treatment

3 months ago

In a significant advancement in cancer therapeutics, the U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca and Daiichi Sankyo's revolutionary drug designed for the treatment of breast cancer. This promising medication is specifically targeted at patients with advanced or metastatic HER2-positive breast cancer, marking a leap forward in therapeutic options for this aggressive form of the disease.

AstraZeneca and Daiichi Sankyo Withdraw EU Application for Lung Cancer Treatment

3 months ago

In a significant development within the pharmaceutical industry, AstraZeneca and its partner Daiichi Sankyo have decided to withdraw their application for the marketing authorization of a lung cancer treatment in the European Union. This decision comes as a blow to both companies, particularly after they had invested substantial resources into the drug's development and regulatory approval.

England's Pricing Negotiations Collapse Over AstraZeneca and Daiichi Sankyo's Breast Cancer Drug

5 months ago

In a significant setback for cancer patients in England, negotiations regarding the pricing of a potentially life-saving breast cancer drug, developed by AstraZeneca and Daiichi Sankyo, have fallen apart. This development leaves many women in need of the medication in a precarious position as they grapple with limited treatment options.